The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?

More than 20 years have passed since the human immunodeficiency virus (HIV)-1 was identified as the cause of AIDS (acquired immune deficiency syndrome). With rapid early progress, the development of a vaccine was predicted within 2-10 years. However, over two decades later, we have seen only a singl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheppard, N, Sattentau, Q
Formato: Journal article
Lenguaje:English
Publicado: 2005
_version_ 1826294702031241216
author Sheppard, N
Sattentau, Q
author_facet Sheppard, N
Sattentau, Q
author_sort Sheppard, N
collection OXFORD
description More than 20 years have passed since the human immunodeficiency virus (HIV)-1 was identified as the cause of AIDS (acquired immune deficiency syndrome). With rapid early progress, the development of a vaccine was predicted within 2-10 years. However, over two decades later, we have seen only a single vaccine candidate complete Phase III clinical efficacy trials. These trials showed the vaccine was not able to protect the trial volunteers from HIV infection or subsequently modify the early clinical progression. It is now accepted that the initial optimism in the field was misguided, as the complexity of the problem stretched beyond the known horizons of vaccinology, immunology and retrovirology. In the intervening 20 years, unprecedented research efforts have pushed the cutting edge of these fields forward to such a degree that we are better able to put the problem of developing a vaccine for HIV-1 into context. Now it is time to examine the prospects for HIV-1 vaccines and ascertain whether real progress is being made.
first_indexed 2024-03-07T03:49:45Z
format Journal article
id oxford-uuid:c0d05ade-c085-4a36-8e7c-300ab826015e
institution University of Oxford
language English
last_indexed 2024-03-07T03:49:45Z
publishDate 2005
record_format dspace
spelling oxford-uuid:c0d05ade-c085-4a36-8e7c-300ab826015e2022-03-27T05:57:05ZThe prospects for vaccines against HIV-1: more than a field of long-term nonprogression?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c0d05ade-c085-4a36-8e7c-300ab826015eEnglishSymplectic Elements at Oxford2005Sheppard, NSattentau, QMore than 20 years have passed since the human immunodeficiency virus (HIV)-1 was identified as the cause of AIDS (acquired immune deficiency syndrome). With rapid early progress, the development of a vaccine was predicted within 2-10 years. However, over two decades later, we have seen only a single vaccine candidate complete Phase III clinical efficacy trials. These trials showed the vaccine was not able to protect the trial volunteers from HIV infection or subsequently modify the early clinical progression. It is now accepted that the initial optimism in the field was misguided, as the complexity of the problem stretched beyond the known horizons of vaccinology, immunology and retrovirology. In the intervening 20 years, unprecedented research efforts have pushed the cutting edge of these fields forward to such a degree that we are better able to put the problem of developing a vaccine for HIV-1 into context. Now it is time to examine the prospects for HIV-1 vaccines and ascertain whether real progress is being made.
spellingShingle Sheppard, N
Sattentau, Q
The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
title The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
title_full The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
title_fullStr The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
title_full_unstemmed The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
title_short The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
title_sort prospects for vaccines against hiv 1 more than a field of long term nonprogression
work_keys_str_mv AT sheppardn theprospectsforvaccinesagainsthiv1morethanafieldoflongtermnonprogression
AT sattentauq theprospectsforvaccinesagainsthiv1morethanafieldoflongtermnonprogression
AT sheppardn prospectsforvaccinesagainsthiv1morethanafieldoflongtermnonprogression
AT sattentauq prospectsforvaccinesagainsthiv1morethanafieldoflongtermnonprogression